For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

Dr. Kara Cicero is a hematologist-oncologist focused on global oncology and cancer disparities research to advance health equity, with specific clinical expertise in multiple myeloma, AL amyloidosis ...

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company’s robust late-stage pipeline could offset ...

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Halozyme Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Kumar holds leadership roles in multiple research initiatives, including serving as Chair of the Myeloma, Amyloidosis, and Dysproteinemia Group. Shaji’s research focuses on hematology and oncology, ...

Pharmac, minister respond Pharmac director of pharmaceuticals Geraldine MacGibbon said it understood the significant impact of multiple myeloma and AL amyloidosis, and was speaking with ...

Randomized clinical trials have established the anti-tumor activity and efficacy of venetoclax in selected patients with hematologic malignancies such as acute myeloid leukemia (AML), chronic ...